12:11 PM EST - CryoCath Technologies : on Tuesday revealed the receipt of U.S. Food and Drug Administration notification allowing company to expand its pivotal Investigational Device or IDE STOP AF trial. According to the company, the FDA approval would enable it to enroll up to 150 patients in up to 20 centers. The Company expects four additional centers to come online in December with the remainder to be actively recruiting patients early in the new calendar year. CryoCath Technologies
shares T.CYT are trading up 17 cents at $2.57.
